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Background: Archived formalin-fixed paraffin-embedded (FFPE) specimens from non-malignant tissues 2 
derived from cancer patients are a vast and potentially valuable resource for high-quality genotyping analyses 3 
and could have a role in establishing inherited cancer risk.  4 
Method: We systematically searched PubMed, Ovid Medline, and Scopus databases for all articles that 5 
compared genotyping performance of DNA from non-malignant FFPE tissue with blood DNA derived from 6 
cancer patients irrespective of tumor type. Two independent researchers screened the retrieved studies, 7 
removed duplicates, excluded irrelevant studies, and extracted genotyping data from the eligible studies. . 8 
These studies included, but were not limited to, genotyping technique, reported call rate, and concordance.  9 
Results: A total of 13 studies were reviewed, in which DNA from non-malignant FFPE tissues derived from 10 
cancer patients was successfully purified and genotyped. All of these studies used different approaches for 11 
genotyping of DNA from non-malignant FFPE tissues to amplify single-nucleotide polymorphisms (SNPs) 12 
and to estimate of loss of heterozygosity (LOH). The concordance between genotypes from non-malignant 13 
FFPE tissues and blood derived from cancer patients was observed to be high, whereas the call rate of the 14 
tested SNPs was not reported in all included studies. 15 
Conclusion: This review illustrates that DNA from non-malignant FFPE tissues derived from cancer patients 16 
can serve as an alternative and reliable source for assessment of germline DNA for various purposes, including 17 
assessment of cancer predisposition. 18 
 19 
 20 




Polymorphisms in germline DNA have a crucial role in cancer predisposition by acting as oncogenic modifiers 2 
or co-oncogenes that determine the needed complementary subsequent somatic changes for full malignant 3 
transformation 1. Numerous germline single-nucleotide polymorphisms (SNPs) have been identified as 4 
predisposing to cancer in several genes, including tumor suppressor genes (e.g., TP53, RB) and genes involved 5 
in DNA repair (e.g., BRCA1, MLH1), cell proliferation (e.g., PTEN, STK11), and cell adhesion (e.g., CDH1, 6 
APC) 2,3. The usual method for studying inherited cancer risks relies on DNA extracted from blood, saliva, or 7 
oral scrapings. However, collection of prospective cohorts of sufficient size, linked with follow-up 8 
information, requires major investments and typically decades of work. As an alternative or additional source 9 
for these studies, the existing non-malignant formalin-fixed paraffin-embedded (FFPE) samples (normal or 10 
benign) in the pathology archives or biobanks can provide easily accessible material for SNP genotyping and 11 
estimation of polygenic cancer risk 4–6.  12 
The greatest challenge with FFPE DNA analysis is caused by the use of formaldehyde in the fixation process. 13 
Formaldehyde leads to formation of crosslinks between DNA and proteins, which causes DNA fragmentation 14 
and subsequent problems in purification and amplification of FFPE DNA 7,8. Extraction of DNA from FFPE 15 
specimens has two major technical difficulties, namely dissolving of paraffin and removal of crosslinks 9. The 16 
feasibility of using DNA extracted from FFPE tissues in various advanced molecular techniques has been 17 
tested. These techniques include whole genome sequencing and high-quality genotyping 10,11.  18 
Although previous studies have examined the genotyping performance of fresh-frozen (FF) tumor tissues and 19 
compared it with matched wild blood genotypes, this approach is still unreliable due to accumulation of 20 
somatic mutations in the tumors 12,13. In addition, these somatic alterations may appear as genotyping errors in 21 
individual SNPs when comparing tumor DNA with normal DNA 14,15. While an alternative could be matched 22 
non-malignant FFPE tissue derived from cancer patients, few reports have utilized this source. By comparing 23 
SNP genotypes generated from non-malignant FFPE tissue and blood DNA derived from cancer patients in 24 
large cohorts, it could be possible to evaluate whether non-malignant FFPE tissue is a viable source of DNA 25 
for large-scale genome-wide association studies (GWAS) that aim to identify genetic factors contributing to 26 





Implementation of GWAS is primarily based on blood samples. In breast cancer patients, GWAS identified 3 
multiple sets of variants with increased susceptibility to cancer, such as prediction of estrogen receptor (ER)-4 
specific disease. This can facilitate stratification of patients with improved detection and management 5 
strategies 18. Additionally, combining several genome risk variants may have enhanced predicative ability in 6 
breast cancer 19,20. Similarly, in lung cancer patients, GWAS-derived polygenic risk scores (PRS) effectively 7 
identified groups with high risk 21. While PRS evaluation may help to guide preventive measures for patients 8 
with significant cancer risk, more studies with large cohorts are needed. An interesting option for cohort 9 
generation is the use of archived pathology collections, which include large numbers of samples from cancer 10 
patients. 11 
We conducted a systematic review of studies that evaluated the performance of the genotyped SNPs in non-12 
malignant FFPE tissues and matched blood samples derived from cancer patients with different malignancies 13 
along with the observed concordance. The main objective was to confirm whether non-malignant FFPE tissue 14 
derived from cancer patients could be used in the future as a source for polygenic risk assessment.  15 
Methods 16 
Search protocol and data sources 17 
We systematically searched for all studies that evaluated genotype concordance between non-malignant FFPE 18 
tissue and blood derived from cancer patients. The systematic search included the PubMed, Ovid Medline, and 19 
Scopus databases from their inception until 17 January 2020. The search included terms (‘genotyping’ OR 20 
‘SNP’) AND (‘concordance’) AND (‘formalin fixed paraffin embedded’ OR ‘FFPE’) AND (‘blood’) AND 21 
(‘cancer’ OR ‘neoplasm’ OR ‘malignant’). Some search terms were replaced with their synonyms and 22 
abbreviations and the searches were repeated. References of the eligible studies were searched manually to 23 
enhance the inclusion of all relevant studies. The Preferred Reporting Items for Systematic Review and Meta-24 
Analysis (PRISMA) guidelines were followed 22. 25 
Inclusion and exclusion criteria 26 
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All original studies that evaluated the genotype concordance between the non-malignant FFPE tissue and blood 1 
derived from cancer patients were included. The search included only articles published in the English 2 
language. We excluded studies that investigated genotyping of malignant FFPE tissues. Additionally, review 3 
articles, case reports, case series, conference abstracts, editorials, letters to the editor, and commentaries were 4 
excluded.  5 
Screening and data extraction 6 
Two independent researchers (OY, AA) screened the systematically retrieved literature at all stages to identify 7 
eligible studies. Disagreements between the two researchers were resolved by discussion to reach a consensus 8 
upon which final studies were included. Extracted data included the following basic information: name of the 9 
first author, publication year, tumor type, and number of matched non-malignant FFPE tissue and blood 10 
samples derived from cancer patients from all eligible studies. Data regarding evaluation of genotyping 11 
included the platform used for both DNA purification and genotyping, sample quality control measures, and 12 
percentage of concordance between non-malignant FFPE tissue and blood genotyping results.  13 
Quality assessment 14 
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system of rating 15 
quality of evidence was used to assess the quality of the eligible studies 23. The quality of evidence ranged 16 
from high to very low and the factors considered to determine the quality of evidence are summarized in Table 17 
1.   18 
Results and Discussion 19 
A total of 152 hits were retrieved, 30 of which were duplicates and 111 were irrelevant studies. Eleven studies 20 
evaluated the genotype concordance between non-malignant FFPE tissue and matched blood samples derived 21 
from cancer patients with various malignancies (Fig. 1). Two additional studies were added manually from 22 
references of the relevant studies; thus, altogether 13 eligible studies were reviewed. The reviewed studies 23 
reported the feasibility of using archived FFPE tissue samples from benign or non-malignant tissues derived 24 
from cancer patients for DNA purification and genotyping approaches using different platforms. In addition, 25 
some of the reviewed studies reported the genotyping call rate and assessed the degree of concordance between 26 
the generated genotypes from the non-malignant FFPE tissue and matched blood samples (Table 2).  27 
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The eligible studies included patients with the following malignancies: three studies on breast cancer 24–26, one 1 
study on breast and ovarian cancer 27, three studies on colorectal cancer 15,28,29, two studies on osteosarcoma 2 
30,31, two studies on prostate carcinoma 32,4, one study on hepatocellular carcinoma 33. Additionally, we included 3 
one computational genotyping study that included SNP data from The Cancer Genome Atlas (TCGA) from 12 4 
major types of malignancies (breast adenocarcinoma, gastric adenocarcinoma, colon adenocarcinoma, rectal 5 
adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma, lung adenocarcinoma, lung squamous 6 
cell carcinoma, prostate adenocarcinoma, ovarian cystadenocarcinoma, head and neck squamous cell 7 
carcinoma, and melanoma) 34. 8 
The number of tested SNPs in the included studies is highly variable, ranging from less than ten SNPs to 9 
hundreds or thousands of tested SNPs according to the genotyping technique used. The tested number of SNPs 10 
was reported to be high with the use of genotyping arrays. The included studies can be classified into small-11 
scale studies (<10 SNPs) and large-scale studies (>200 SNP) according to the number of tested SNPs. 12 
The small-scale studies group included seven studies. By focusing on cancer type, a study by Xie et al analyzed 13 
five variants in genes typically showing LOH in breast cancer (MTHFR, hOGG1, DBH, DRD2, NQO1) and 14 
reported 100% concordance between non-malignant FFPE tissue and blood derived from breast cancer patients 15 
24. Due to the crucial role of the CYP2D6 enzyme in anti-estrogen hormonal therapy, Rae and colleagues 25 16 
investigated CYP2D6 genotypes in FFPE lymph nodes and compared them to blood-derived genotypes and 17 
revealed a concordance of 97.4%. In hereditary breast cancer, a 100% genotype concordance rate was seen 18 
between non-malignant FFPE tissue and blood when investigating the BRCA1 and BRCA2 founder mutations 19 
27.  20 
The results were controversial in colorectal cancer (CRC). When performing LOH amplification assays in 21 
CRC, the data were not always consistent. On one hand, the concordance in the allelic ratio between normal 22 
colonic mucosa and matched blood using PCR was above 85% in 64% of the samples 29. The authors 23 
recommended normalization of tumor allele ratios with matched normal tissue samples 29. On the other hand, 24 
a study performed by Marisi et al reported that at the specific marker VEGF −1154 G>A the concordance 25 
between non-malignant FFPE and blood derived from CRC was 57% (4 out of 7 samples) 15. Marisi et al added 26 
that the concordance was much higher (up to 100%) at other VEGF markers; (−2578C>A, −1498C>T, 27 
−1154G>A, −634C>G, +936C>T) and eNOS markers (+894G>T, −786T>C, VNTR [variable number of 28 
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tandem repeats] 27bp intron 4) when comparing malignant FFPE tissue with matched blood-derived DNA 15. 1 
Although the authors could not conclude whether the loss of guanine in VEGF −1154 G>A was due to a FFPE 2 
fixation effect or real tumor alterations, they recommended special precautions when analyzing SNPs with C 3 
or G alleles along with optimization of FFPE DNA extraction and genotyping methods 15.  4 
Importantly, C-T or G-A transitions are common events that may occur due to the formalin fixation procedure 5 
to FFPE and can produce sequence artifacts in different amplification procedures such as PCR 35,36. However, 6 
use of uracil DNA glycosylase (UDG), an enzyme involved in base excision repair greatly enhanced the quality 7 
of purified FFPE DNA with regard to DNA integrity and fragment length 37. Pretreatment of FFPE tumor 8 
tissues with UDG reduced the amount of artifactual variants when applying next-generation sequencing and 9 
eliminated variants with low allele frequencies 38.  10 
A study on osteosarcoma tested two SNPs in the drug transporter gene MDR1 and showed a 90% success rate 11 
in genotyped FFPE normal specimens using a PCR TaqMan-based approach 30. The last study in the group of 12 
small-scale studies was performed on hepatocellular carcinoma (HCC), where the authors performed allele-13 
specific amplification and TaqMan assays before and after whole-genome amplification. Genotypes were 14 
considered successful when the same results were obtained twice by both gel electrophoresis and TaqMan 15 
assays 33.  16 
The group of large-scale analysis included six studies. By following the same approach of focusing on cancer 17 
type, Hertz et al analyzed 247 SNPs in FFPE lymph nodes and blood from breast cancer patients using the 18 
Sequenom MassARRAY (the University of Michigan DNA Sequencing core). They reported a genotype 19 
concordance rate of 99.7% and call rate of 97%, indicating that heterozygous genotypes were often not or 20 
discordantly called 26.  21 
In CRC patients, Lips et al performed a comparison of non-malignant FFPE tissue and blood using Illumina 22 
BeadArrays in combination with the linkage mapping panel version 4, revealing 99.4% genotype concordance 23 
with LOH detected on chromosomes 4, 5q, 12q, 14q, 15q, 17p, 18, and 20p, which commonly show LOH in 24 
CRC 28. In comparison with the LOH analysis in the CRC small-scale studies group, Lips et al illustrated the 25 
different advantages of using genotyping arrays in LOH detection, such as large numbers of tested SNPs in 26 
one experiment, applying quality criteria to remove calls from poorly amplified genotypes, and the ability to 27 
calculate call rate for each SNP individually, and to estimate the concordance with matched blood genotypes.  28 
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In osteosarcoma patients, non-malignant FFPE tissues were tested on a platform called the drug-metabolizing 1 
enzymes and transporters (DMET) Plus Array (Thermo Fischer Scientific). The array includes 231 genes and 2 
1936 variants covering all pharmacogenetic characteristics such as drug absorption, distribution, metabolism, 3 
excretion, and transport. The reported call rate was 98.9% ± 1.0%, which was comparable to the blood call 4 
rate of 99.4% ± 0.30%. 31. The overall genotyping concordance in all 1936 variants included in the DMET 5 
array was 97.4%. Of note, after removal of no calls and possible rare allele calls, the concordance exceeded 6 
99% except for two samples 31.     7 
In prostate carcinoma patients, the genotyping call rates were high from matched normal tissue FFPE from 8 
both urethra (97%) and seminal vesicles (95.9%) 4. To resolve the misclustering issue that may affect the 9 
concordance estimates, the authors omitted variants with a minor allele frequency (MAF) less than 5%, which  10 
reduced the number of tested SNPs from 416 047 to 127 847 4. Similarly, Cannon-Albright used the Illumina 11 
550k SNP data set to select markers that can represent the entire genome with a median heterozygosity of 0.49 12 
and median spacing of 0.14cM. They revealed 99% concordance by testing normal FFPE tissue and matched 13 
blood samples from two patients 32.  14 
Finally, a comprehensive computational approach analyzed a TCGA SNP data platform that used an 15 
Affymetrix 6.0 SNP array in several malignancies and reported significantly higher concordance in blood-16 
normal tissue pairs (99.17%) than blood-tumor tissue pairs (96.9%) (p=1.1 x 10-44) 34. The authors concluded 17 
that quality control practices are a vital step in the analysis of genotyping array data. 18 
Preanalytical variables that affect sample handling (both FFPE and blood) is a crucial issue and should be 19 
considered when dealing with bio-specimens 39. In the reviewed studies, only five out of 13 reported the age 20 
of the stored blocks (3/5 also reported the storing temperature), and only three out of 13 discussed the details 21 
of their fixation process. The overall quality of the outcomes from the published studies was assessed as 22 
moderate to high (Table 1). Some of the published studies suffered from limitations, such as a small number 23 
of analyzed matched FFPE tissue and blood samples, a small number of tested SNPs, or no reported call rate, 24 
concordance, or both (Table 2). We were not able to perform a meta-analysis because of the heterogeneity 25 
between DNA purification and genotyping techniques in the published studies. 26 
Importantly, the reported overall concordance and call rate in the reviewed studies are influenced by three 27 
essential elements, including the number of tested paired blood-normal tissue samples, the number of analysed 28 
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SNPs, and the genotyping technique used (PCR or a customized array). Considering the earlier classification 1 
of the studies into small-scale and large-scale studies, it is clearly apparent that the former group that applied 2 
PCR assays with specific primers and probes reported a high concordance (usually ranging from 97.4% to 3 
100%). The studies in the latter group used arrays that tested for a large number of SNPs and reported a slightly 4 
lower concordance (ranging from 92.5% to 99.7%). However, in the group of large-scale studies, the overall 5 
genotyping call rate was reported in most of the studies (4 out of 6), thus giving a better idea about the quality 6 
of genotyped SNPs.   7 
Assessment of both sample and SNP quality control is a crucial step when working with arrays. One of the 8 
possible explanations for the observed decreased concordance in arrays can be explained by misclustering, 9 
which makes it difficult for the genotype clustering algorithms to distinguish heterozygotes from major allele 10 
homozygotes, thus causing a false increase in heterozygosity 4. For a rare variant with MAF below 5%, it is 11 
still challenging for different algorithms to perform accurate clustering. To control the effect of poor genotype 12 
clustering in rare SNPs, Emami et al applied an analytical maneuver that removes SNPs that violate Hardy–13 
Weinberg equilibrium (HWE), which leads to a significant decrease in heterozygosity in both blood and normal 14 
tissue genotypes to the expected levels. Although more stringent SNP quality control enhances the accuracy 15 
of genotyped calls, it may also eliminate large numbers of accurate genotype calls from the final dataset 4. 16 
Perreault et al performed a comparison of four different clustering tools (GenCall, GenoSNP, optiCall and 17 
zCall) for analysis of rare variants using the Illumina HumanExome BeadChip, which includes 247 870 SNPs 18 
and uses the 1000 Genomes Project as a reference. The authors also concluded that using multiple clustering 19 
algorithms in a parallel manner enhances identification of discordant SNPs 40.  20 
Other study types (not included in this systematic review) evaluated the genotyping concordance of malignant 21 
FFPE tissue with blood. These studies revealed a widely variable concordance rate, ranging from 54.6% in 22 
early stage non-small cell lung carcinoma 41 to approximately 100% in other tumors, such as CRC and 23 
lymphoma 42,43. Several factors seem to influence the concordance rate in genotyping of tumor tissues, 24 
including tumor type, tumor stage, and most importantly the influence of somatic alterations and tumor 25 
heterogeneity that occur in cancer 12,13. Low FFPE DNA quality can cause low SNP genotyping concordance. 26 
Additionally, the rate of no-call genotype is higher in tumor FFPE than in normal tissue FFPE due to the 27 
hypermutation status in tumor tissues 34.  28 
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A major factor that affects the SNP genotyping process is the quality of the original FFPE DNA and its yield. 1 
Most of the included studies used Qiagen kits for DNA extraction (9 out of 13), which rely on the same 2 
principle of silica column-based DNA purification methods, resulting in uniform extracted DNA in terms of 3 
purity and quantity. However, only seven out of the total 13 reviewed studies illustrated the methodology used 4 
for FFPE DNA quality assessment such as Nanodrop assay, gel electrophoresis, PicoGreen fluorescence, or 5 
PCR. Only four out of these seven studies mentioned their FFPE DNA quality parameters, such as reporting 6 
A260/280 ratio of 1.8 32, DNA concentration in the range of 0.9-18.4µg by using the QIAamp method 33, and 7 
amplicon size range of 100 to 300bp 30,31.  8 
In this sense, the minimum DNA fragment length that can be successfully genotyped by a TaqMan assay was 9 
reported to range from 100 to 400 bp, whereas the DNA quantity required for successful TaqMan genotyping 10 
ranged from 1 pg to 10 ng 10. For SNP arrays, the starting FFPE DNA input varied from 50 ng/µL (after 11 
normalization) when using an Affymetrix Mendel Nsp 250K chip 44 to 400 ng when using the 12 
HumanOmni5Exome BeadChip 45. Interestingly, DNA yield from 2 x 10 μm sections and 0.6 mm cores from 13 
the same paraffin blocks was quite comparable; 92.3% to 100% concordant genotypes per given SNP between 14 
the matched cores and sections were observed 10. To facilitate DNA purification from FFPE tissue samples, 15 
new techniques and methods have been developed to enhance DNA yield for accurate genotyping purposes. 16 
An automated FFPE DNA extraction procedure was reported to successfully extract DNA with adequate 17 
quality and quantity for SNP genotyping in Affymetrix Genome-Wide Human 6.0 arrays and TaqMan SNP 18 
PCR 46.  19 
Another crucial element is the possibility of optimizing the FFPE DNA extraction methodology to purify DNA 20 
of high quality and sufficient concentration for downstream molecular reactions, such as sequencing. Recently, 21 
Frazer et al used one FFPE DNA extraction kit (QIAamp DNA FFPE Tissue) to test three different 22 
modifications to the protocol. The authors applied different amounts of proteinase K (20 µl versus 40 µl) and 23 
different incubation periods (24 hours versus 72 hours), and observed that 40 µl proteinase K with a 24-hour 24 
incubation gave the highest DNA yield with good DNA integrity 47.  25 
Furthermore, Bonnet et al performed a comparison of three different FFPE DNA extraction kits (QIAamp 26 
DNA FFPE Tissue kit and GeneRead DNA FFPE kit from Qiagen and Maxwell™ RSC DNA FFPE Kit from 27 
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Promega) along with their performance on an exome sequencing platform 48. The authors reported superiority 1 
of both Qiagen kits regarding DNA quality and median coverage of the mapped reads in the sequencing data 2 
48. Interestingly, the authors evaluated the FFPE artifacts in the three kits through paired sequencing of the 3 
FFPE samples with the matching fresh-frozen (FF) samples by calculating the difference in the number of 4 
variants for each pair of matched FF/FFPE samples for both single-nucleotide variants (SNVs) and insertions 5 
and deletions (INDELs). The authors observed the lowest variations with the GeneRead kit, which emphasizes 6 
the importance of UDG in FFPE pretreatment and its role in removal of FFPE artifacts 48.  7 
Importantly, almost half of the included studies (6/13) used whole blood-derived DNA as a reference against 8 
which concordance was calculated, and reported concordance (four out of these six studies) from 92.5% to 9 
100%. Two other studies used blood and saliva derived DNA with reported concordance of 97.4% to 100%. 10 
In addition, three studies used leukocyte derived DNA and one study used lymphocyte derived DNA with 11 
reported concordance of 97.4% to 99.7% and 100%, respectively. DNA derived from plasma and serum was 12 
used in one study with no reported concordance rate (Table 2). The reviewed studies did not provide clear 13 
evidence that refers to the difference in the concordance rate to the source of blood derived DNA used as a 14 
reference. Indeed, a crucial and future aim is to incorporate genotyping arrays for DNA extracted from FFPE 15 
tissue into clinical applications. Lyons-Weiler et al optimized the Affymetrix GeneChip 10k 2.0 assay for 16 
assessment of LOH and copy number alterations in routine clinical use from malignant FFPE tissue specimens 17 
49. Although Lyons-Weiler and colleagues did not test the protocol for non-malignant FFPE tissues derived 18 
from cancer patients, they reported 96% concordance with the genotyping data from fresh tumor tissues 49.  19 
In conclusion, our systematic review identified only a few studies that compared both normal tissue FFPE and 20 
blood derived DNA derived from cancer patients as a source for large-scale germline genotyping. Importantly, 21 
these studies, and studies that used only few selected SNPs, show that DNA extracted from non-malignant 22 
FFPE tissue specimens derived from cancer patients can be successfully genotyped using different genotyping 23 
methods. Our review confirms the feasibility of using non-malignant FFPE tissue derived from cancer patients 24 
for analysis of germline DNA. However, systematic studies with larger sample sizes that assess qualitative 25 
factors and compare the recently introduced methods for improving FFPE DNA yield and quality are still 26 
needed to demonstrate the applicability of archived normal FFPE specimens in the evaluation of polygenic 27 
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The quality of evidence was assessed using the GRADE approach. 
Factors that reduce the quality of the evidence: risk of bias (limitations in the study design), inconsistency of results, indirectness of evidence, imprecision, and publication 
bias. 
Factors that increase the quality of the evidence: large effect size, dose-response gradient, all plausible confounding would reduce a demonstrated effect, all possible 
confounding would suggest a spurious effect when the actual results show no effect.  
High quality: We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate quality: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is 
markedly different. 
Low quality: Our confidence in the effect estimate is limited; the true effect may be markedly different from the estimate of the effect. 
Very low quality: We have very little confidence in the effect estimate; the true effect is likely to be markedly different from the estimate of effect. 
a Different methods for DNA genotyping and some studies have no reported call rate; this could have a potential effect on the quality of the results. 
b Some studies have no reported concordance ratio; this could have a potential effect on the quality of the results.  
 
 
TABLE 2. SUMMARY OF STUDIES THAT EXAMINED GENOTYPING CONCORDANCE BETWEEN NON-MALIGNANT FFPE AND BLOOD-
DERIVED DNA FROM CANCER PATIENTS. 
First 
author, year 










with UDG  
Source of blood 
derived DNA 







Zauber et al, 
1999 
CRC 28 QIAmp Tissue 
Kit 
Not used Whole blood PCR assay 1 NA NA 
Sjӧholm et 
al, 2005 
HCC 31 QIAquick and 
QIAamp 
Not used Plasma and serum Restriction fragment 
length polymorphism 
(RFLP) and TaqMan 
PCR assay  
4 NA NA 
Lips et al, 
2005 
CRC 2 Chelex 
extraction 
Not used Leukocytes SNP array genotyping 
(Illumina Bead Arrays) 
5861 NA 99.4 
Xie et al, 
2006 
Breast 106 MagAttract 
DNA 
Mini M48 Kit  
Not used Whole blood TaqMan PCR assay 5 NA 100 




161 NA Not used Lymphocytes PCR assay 
 
3 NA 100 
Hagleitner et 
al, 2011 
Osteosarcoma 18 DNeasy 
Tissue kit 




Prostate 2 QIAamp DNA 
FFPE Tissue Kit 
Not used Whole blood SNP array genotyping 
 
27 157 88-98 99 
Rae et al, 
2013 
Breast 122 NA Not used Leukocytes TaqMan PCR assay 1 NA 97.4 
Marisi et al, 
2014 
CRC 20 QIAamp DNA 
Micro kit 
Not used Whole blood TaqMan PCR assay 7 NA NA 
Vos et al, 
2015 
Osteosarcoma 16 QIAamp DNA 
Micro Kit 
Not used Blood and saliva SNP array genotyping 
(DMET) 
1931 98.9 97.4 
Hertz et al, 
2015 
Breast 114 Qiagen DNeasy 
Blood 
and Tissue 
Not used Leukocytes SNP array genotyping 
(Sequenom Mass 
arrays) 
247 97 99.7 
Emami et al, 
2017 
Prostate 31 QIAamp DNA 
FFPE Tissue Kit 
Not used Whole blood SNP array genotyping 
(Affymetrix Axiom 2.0) 
416 047 Urethra 97 
and seminal 
vesicle 95.9 
















426 NA NA Whole blood SNP array genotyping 
(Affymetrix 6.0 SNP 
data set) 
>906 600 NA 99.17 
NA not available, HCC hepatocellular carcinoma, CRC colorectal carcinoma, BRCA breast adenocarcinoma, COAD colon adenocarcinoma, HNSC head and neck squamous cell 
carcinoma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, OV ovarian cystadenocarcinoma, PAAD pancreatic 
adenocarcinoma, PRAD prostate adenocarcinoma, READ rectal adenocarcinoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, UDG uracil DNA glycosylase 
enzyme, DMET drug metabolizing enzymes and transporters plus array. 
 
FIG. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart. The chart shows 
the number of articles identified and the number of articles excluded along with the steps of systematic searching for 
studies that examined genotyping concordance between DNA derived from non-malignant FFPE and blood from cancer 
patients.   
 
